Gan & Lee Pharmaceuticals Co Ltd - Asset Resilience Ratio
Gan & Lee Pharmaceuticals Co Ltd (603087) has an Asset Resilience Ratio of 9.08% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Gan & Lee Pharmaceuticals Co Ltd balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2024)
This chart shows how Gan & Lee Pharmaceuticals Co Ltd's Asset Resilience Ratio has changed over time. See net assets of Gan & Lee Pharmaceuticals Co Ltd for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Gan & Lee Pharmaceuticals Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Gan & Lee Pharmaceuticals Co Ltd worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥1.10 Billion | 9.08% |
| Total Liquid Assets | CN¥1.10 Billion | 9.08% |
Asset Resilience Insights
- Limited Liquidity: Gan & Lee Pharmaceuticals Co Ltd maintains only 9.08% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Gan & Lee Pharmaceuticals Co Ltd Industry Peers by Asset Resilience Ratio
Compare Gan & Lee Pharmaceuticals Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Alcon AG
SW:ALC |
Medical Instruments & Supplies | 0.26% |
|
iRay Technology Co Ltd
SHG:688301 |
Medical Instruments & Supplies | 0.68% |
|
Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNN |
Medical Instruments & Supplies | 29.19% |
|
Jiangsu Nanfang Medical
SHG:603880 |
Medical Instruments & Supplies | 2.27% |
|
SDI Ltd
AU:SDI |
Medical Instruments & Supplies | 6.36% |
|
I.Ceram SA
PA:ALICR |
Medical Instruments & Supplies | -1.61% |
|
Ansell Ltd
AU:ANN |
Medical Instruments & Supplies | 4.42% |
|
Nanosonics Ltd
AU:NAN |
Medical Instruments & Supplies | 51.82% |
Annual Asset Resilience Ratio for Gan & Lee Pharmaceuticals Co Ltd (2019–2024)
The table below shows the annual Asset Resilience Ratio data for Gan & Lee Pharmaceuticals Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 12.46% | CN¥1.50 Billion ≈ $219.57 Million |
CN¥12.04 Billion ≈ $1.76 Billion |
-8.12pp |
| 2023-12-31 | 20.58% | CN¥2.41 Billion ≈ $352.72 Million |
CN¥11.72 Billion ≈ $1.71 Billion |
+5.15pp |
| 2022-12-31 | 15.42% | CN¥1.64 Billion ≈ $239.39 Million |
CN¥10.61 Billion ≈ $1.55 Billion |
+0.46pp |
| 2021-12-31 | 14.97% | CN¥1.62 Billion ≈ $237.67 Million |
CN¥10.85 Billion ≈ $1.59 Billion |
+6.69pp |
| 2020-12-31 | 8.28% | CN¥787.05 Million ≈ $115.17 Million |
CN¥9.51 Billion ≈ $1.39 Billion |
-9.28pp |
| 2019-12-31 | 17.56% | CN¥1.06 Billion ≈ $154.86 Million |
CN¥6.03 Billion ≈ $881.89 Million |
-- |
About Gan & Lee Pharmaceuticals Co Ltd
Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the research, development, production, and sale of insulin analog active pharmaceutical ingredients (APIs) and injections in China. Its products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro injection; Prandilin 25, an insulin lispro mix 75/25 injection; Rapilin, an insulin aspart injection; Rapilin… Read more